![Melissa M. Yoon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Melissa M. Yoon
Algemeen Adviseur bij Ambry Genetics Corp.
Actieve functies van Melissa M. Yoon
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Ambry Genetics Corp.
![]() Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Algemeen Adviseur | - | - |
Loopbaan van Melissa M. Yoon
Eerdere bekende functies van Melissa M. Yoon
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Bedrijfssecretaris | 12-10-2020 | - |
Statistieken
Internationaal
Verenigde Staten | 3 |
Operationeel
General Counsel | 1 |
Corporate Secretary | 1 |
Sectoraal
Commercial Services | 2 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Ambry Genetics Corp.
![]() Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Commercial Services |
Akcea Therapeutics, Inc.
![]() Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Melissa M. Yoon
- Ervaring